Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have been assigned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $7.00.
Several analysts recently commented on the company. Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, May 6th. Morgan Stanley reduced their price objective on Recursion Pharmaceuticals from $8.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, June 16th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th.
Get Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Up 4.7%
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter last year, the business posted ($0.39) earnings per share. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. Equities research analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of RXRX. Brighton Jones LLC boosted its position in shares of Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after acquiring an additional 6,699 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Recursion Pharmaceuticals by 7.6% during the 4th quarter. Rhumbline Advisers now owns 334,032 shares of the company’s stock worth $2,258,000 after acquiring an additional 23,564 shares in the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter worth about $75,000. Global Retirement Partners LLC boosted its position in shares of Recursion Pharmaceuticals by 31.5% during the 4th quarter. Global Retirement Partners LLC now owns 31,297 shares of the company’s stock worth $212,000 after acquiring an additional 7,500 shares in the last quarter. Finally, Private Advisor Group LLC boosted its position in shares of Recursion Pharmaceuticals by 103.8% during the 4th quarter. Private Advisor Group LLC now owns 31,427 shares of the company’s stock worth $212,000 after acquiring an additional 16,008 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
- Five stocks we like better than Recursion Pharmaceuticals
- The How And Why of Investing in Oil Stocks
- Astera Labs: AI Infrastructure Play With Significant Growth Ahead
- Bank Stocks – Best Bank Stocks to Invest In
- Is IBM’s AI Transformation Powering a Sustained Rally?
- Trading Stocks: RSI and Why it’s Useful
- NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.